All In Biotech

Drug Trial Radar · NCT07365241

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 531 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

531

Planned (sponsor's estimate)

Start

Jul 2, 2026

Primary completion

Sep 2030

Study completion Sep 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide. Participants with SCLC will receive intravenous (IV) ABBV-706 or SOC \[topotecan (IV or orally), or lubinectedin (IV), or amrubicin (IV)\]. The estimated duration of the study is approximately 53 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Conditions

  • Small Cell Lung Cancer

Interventions

  • ABBV-706Drug

    Intravenous (IV) Infusion

  • TopotecanDrug

    IV Infusion

  • TopotecanDrug

    Oral

  • LurbinectedinDrug

    IV Infusion

  • AmrubicinDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)Time frame: Up to approximately 24 months
  2. Overall Survival (OS)Time frame: Up to approximately 28 months

Locations

72 sites in 10 countries. Site status is shown where the registry gives one.

  • Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063

    Birmingham, Alabama · Recruiting

  • Usa Mitchell Cancer Institute /ID# 280198

    Mobile, Alabama · Recruiting

  • City Of Hope - Phoenix /ID# 281323

    Goodyear, Arizona · Recruiting

  • City of Hope National Medical Center /ID# 281322

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396

    Irvine, California · Recruiting

  • Florida Cancer Specialists & Research Institute - South /ID# 281387

    Fort Myers, Florida · Recruiting

  • Orlando Health Cancer Institute /ID# 280418

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center /ID# 279732

    Tampa, Florida · Recruiting

  • City Of Hope - Atlanta /ID# 279929

    Newnan, Georgia · Recruiting

  • University of Chicago Medical Center /ID# 280149

    Chicago, Illinois · Recruiting

  • OSF St. Francis Medical Center /ID# 279930

    Peoria, Illinois · Recruiting

  • Springfield Clinic - First /ID# 281309

    Springfield, Illinois · Recruiting

  • City Of Hope - Chicago /ID# 281335

    Zion, Illinois · Recruiting

  • Franciscan St. Francis Health /ID# 279788

    Indianapolis, Indiana · Recruiting

  • Baptist Health Louisville /ID# 280025

    Louisville, Kentucky · Recruiting

  • Dana-Farber Cancer Institute /ID# 279690

    Boston, Massachusetts · Recruiting

  • Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955

    Grand Rapids, Michigan · Recruiting

  • Minnesota Oncology - Edina Clinic /ID# 280698

    Edina, Minnesota · Recruiting

  • Mayo Clinic Hospital Rochester /ID# 279784

    Rochester, Minnesota · Recruiting

  • Inspira Medical Center Mullica Hill /ID# 280574

    Mullica Hill, New Jersey · Recruiting

  • FirstHealth of the Carolinas- Speciality Center /ID# 279857

    Pinehurst, North Carolina · Recruiting

  • Oncology Hematology Care - Fairfield /ID# 280641

    Fairfield, Ohio · Recruiting

  • Willamette Valley Cancer Institute and Research Center /ID# 280617

    Eugene, Oregon · Recruiting

  • Oregon Health and Science University /ID# 280071

    Portland, Oregon · Recruiting

  • St. Lukes University Hospital /ID# 280204

    Bethlehem, Pennsylvania · Recruiting

  • Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619

    Knoxville, Tennessee · Recruiting

  • University Of Tennessee Medical Center /ID# 279896

    Knoxville, Tennessee · Recruiting

  • Baptist Memorial Hospital /ID# 281405

    Memphis, Tennessee · Recruiting

  • SCRI Oncology Partners /ID# 279779

    Nashville, Tennessee · Recruiting

  • Vanderbilt University Medical Center /ID# 280169

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center /ID# 280070

    Houston, Texas · Recruiting

  • Texas Oncology - Northeast Texas /ID# 280642

    Tyler, Texas · Recruiting

  • Blue Ridge Cancer Care - Blacksburg /ID# 281583

    Blacksburg, Virginia · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 280710

    Fairfax, Virginia · Recruiting

  • Shenandoah Oncology /ID# 280699

    Winchester, Virginia · Recruiting

  • West Virginia University Hospitals /ID# 279883

    Morgantown, West Virginia · Recruiting

  • University of Wisconsin /ID# 279909

    Madison, Wisconsin · Recruiting

  • Universitaetsklinikum Krems /ID# 280608

    Krems, Lower Austria, Austria · Recruiting

  • Ordensklinikum Linz Elisabethinen /ID# 281314

    Linz, Upper Austria, Austria · Recruiting

  • AZ-Delta. /ID# 280341

    Roeselare, West-Vlaanderen, Belgium · Recruiting

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.